Thrombophilia Screening After Severe IUGR

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT05551078
Collaborator
(none)
100
1
3.5
28.2

Study Details

Study Description

Brief Summary

This retrospective study aims to assess the input of thrombophilia screening in pregnant women with severe intra-uterine growth restricted babies.

Condition or Disease Intervention/Treatment Phase
  • Biological: thrombophilia screening

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Thrombophilia Screening in Women After Severe IUGR
Actual Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
pregnant women with severe IUGR

Biological: thrombophilia screening
In the IUGR group systematic thrombophilia screening had already been performed.

Outcome Measures

Primary Outcome Measures

  1. Rate of positive's thrombophilia screening [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women over 18 years old

  • Pregnant women

  • IUGR defined by an EFW <3rd centile

  • IUGR before 25 GW

Exclusion Criteria:
  • none

Contacts and Locations

Locations

Site City State Country Postal Code
1 Matthieu Dap Nancy France 54000

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT05551078
Other Study ID Numbers:
  • 2022PI102
First Posted:
Sep 22, 2022
Last Update Posted:
Sep 22, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2022